Motor control research lab
Urbana, Illinois, 61801, United States
NCT Number: NCT02274935
This study examines the effect of balance and walking exercise on cognition and mobility in people with Multiple Sclerosis.
Looking for future studies?
Notify Me18 year–64 year
All sexes
Interventional
Not applicable
Urbana, Illinois, 61801, United States
Walking and cognitive impairments are common in persons with multiple sclerosis (MS). Approximately 85% of persons with MS report walking as a major limitation, whereas 65% experience cognitive dysfunction. Traditionally, walking and cognition have been viewed as unrelated, but there is evidence of cognitive-motor interference (CMI). CMI is believed to stem from damage to common neural tracts. Recent evidence supports cognitive-motor interference in persons with MS. For example, there is evidence that walking performance declines when performed in conjunction with a simultaneous cognitive task (i.e., dual task cost [DTC] of walking) and this decline in walking performance is greater in persons with MS compared to healthy controls. This elevated cognitive-motor interference during walking is mainly associated with walking performance in persons with MS although cognitive function does play a role. Cognitive-motor interference during mobility tasks is of practical and clinical importance because it has been linked to decreased community mobility and a greater risk of falls in other clinical populations. Despite the adverse consequences of elevated CMI there is ambiguity concerning prevention and rehabilitation strategies for cognitive-motor interference in individuals with MS.
This study seeks to examine whether single and/or targeted dual task rehabilitation has a beneficial effect on CMI in individuals with MS. The results of this investigation will provide the foundation for future rehabilitation-based randomized control trials seeking to improve walking and cognitive function in persons with MS.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Physician diagnosed MS, relapse free for 30 days, self reporting problems with multitasking -
Exclusion criteria
We will exclude all individuals with risk factors contra-indicative for undertaking strenuous exercise. Participants will verbally respond to a health history questionnaire. Those individuals who are asymptomatic and meet no more than one risk factor threshold including family history of coronary heart disease, cigarette smoking, hypertension, high cholesterol, diabetes, obesity, and sedentary lifestyle will be considered at low risk and included for participation.
-
Balance and gait exercise twice a week for an hour
Other names: Physical Rehabilitation
Time frame: 12 weeks
This will be operationalized as the percent change in walking velocity from single (walking only) to dual task (walking while thinking). Participants will complete a total of 8 walking trials over a 20' pressure sensitive (Zeno™) walkway. Four at a comfortable walking speed and four as fast as possible. Half of the trials at each speed will be conducted while reciting every other letter of the alphabet (i.e. N, P, R, etc).
University of Illinois at Urbana-Champaign
Other
Acronym: DUETS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03963375
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
St Louis, Missouri, United States
View Trial DetailsNCT02511028
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Bethesda, Maryland, United States
View Trial DetailsNCT07175792
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Diepenbeek, Belgium
View Trial DetailsNCT07726667
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Gaziantep, Gaz, Turkey (Türkiye)
View Trial Details